The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

Human Chorionic Gonadotropin

FDA-approved · Grade B

Goals
hormonal, libido, muscle
Evidence
14 RCT / 0 animal / 0 in vitro
Routes
injectable-sc, injectable-im
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
The 36-hour half-life of hCG vs LH's 30 minutes reflects the CTP extension's protective effect against renal clearance and plasma peptidase degradation
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Oxytocin

FDA-approved · Grade C

Goals
cognition, libido, hormonal
Evidence
10 RCT / 5 animal / 3 in vitro
Routes
injectable-sc, injectable-im, nasal
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
plasma half-life approximately 1-6 minutes (rapidly degraded by oxytocinases, primarily cystyl aminopeptidase/leucyl-cystinyl aminopeptidase)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Enclomiphene

Off-label · Grade C

Goals
hormonal, libido, muscle
Evidence
4 RCT / 1 animal / 2 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
short plasma half-life (estimated ~10-12 hours in humans under repeated dosing)
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

HGH / Somatropin

FDA-approved · Grade C

Goals
muscle, healing, sleep, weight-loss
Evidence
10 RCT / 3 animal / 2 in vitro
Routes
injectable-sc, injectable-im
WADA
S2
FDA
Approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →